FI4051688T3 - Cd73:n estäjiä - Google Patents
Cd73:n estäjiä Download PDFInfo
- Publication number
- FI4051688T3 FI4051688T3 FIEP20883288.1T FI20883288T FI4051688T3 FI 4051688 T3 FI4051688 T3 FI 4051688T3 FI 20883288 T FI20883288 T FI 20883288T FI 4051688 T3 FI4051688 T3 FI 4051688T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- pharmaceutically acceptable
- cancer
- acceptable salt
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (20)
1. Yhdiste, joka valitaan seuraavista: NNH Å No - N J 4 ON ¢ = A 2 N NN JO e MÄ A 6 PUN vo HÖ ÖH , O HEN "O Na | i Yeo VTX O A G N i . Ho NT N OS HO OH . HN-N HN NA ot AA 0 Lin 0 J 2 5 o eli HO ST HO OH , Sap N p” i HN 35° m O NEN Ou KR Oil A woh ONT N a OH = HÖ OH NN HN, J D NN HN oJ" MYÖ 4 Z O. Ni A -P 0 N Te ma TNT KÖ OM , NN KN MN <A > NÖN År ÖL OH A o NT A n A O pun Ho-P NJ Ne HO HÖ ÖH ,
EP4051688 2 2 D s JN mn a X YTY VT OH f p < OVAN | Aa HOI Vi OH Ft HG OH . OH HN 8 OT NOY Öö O ST HG OH on 0 Oa NH NES N Ho PH OL A PRO Y No O W — | HÖ OH Neg HN A A D NI NON Q O N i A Ho-P Nr Ne HO - - HÖ OH , NaN A N r HM, <. AN NÄS o_o n A = NT N Oz n O JNA oe HO < i HÖ OK , ja n EN SN ne N ~/ n LA Rt of yt Na HO OH € HO OH : tai sen farmaseuttisesti hyväksyttävä suola.
2. Patenttivaatimuksen 1 mukainen yhdiste, jolloin kyseinen yhdiste on
EP4051688 3 Non 3 JA QO op D ON FT 7 N OX O YI Pp G e: 3 OT N a HÖ OH : tai sen farmaseuttisesti hyväksyttävä suola.
3. Patenttivaatimuksen 1 mukainen yhdiste, jolloin kyseinen yhdiste on OI NI "O HO oN yi wa HÖ OH ; tai sen farmaseuttisesti hyväksyttävä suola.
4. Patenttivaatimuksen 1 mukainen yhdiste, jolloin kyseinen yhdiste on HN-N HN 195 KÄY as Ko”? ON OSAN a HÖ ON : tai sen farmaseuttisesti hyväksyttävä suola.
5. Patenttivaatimuksen 1 mukainen yhdiste, jolloin kyseinen yhdiste on Sn Å ~ LN Ww a K WC N M O i G of, © NY Va HO OH : tai sen farmaseuttisesti hyväksyttävä suola.
6. Patenttivaatimuksen 1 mukainen yhdiste, jolloin kyseinen yhdiste on Ne ! MA JO OL OH NA N NYA Ho HÖ OH : tai sen farmaseuttisesti hyväksyttävä suola.
EP4051688
4
7. Patenttivaatimuksen 1 mukainen yhdiste, jolloin kyseinen yhdiste on NN CA \ A uy S ÖL OH ” A N a NZ | TN i N A 2 0 N Ci "hd OT HÖ ÖH ; tai sen farmaseuttisesti hyväksyttävä suola.
8. Patenttivaatimuksen 1 mukainen yhdiste, jolloin kyseinen yhdiste on o n JM uy S Hori, Nr Noi HO OH ; tai sen farmaseuttisesti hyväksyttävä suola.
9. Patenttivaatimuksen 1 mukainen yhdiste, jolloin kyseinen yhdiste on on A Jy NN NEN SON? NR | HÖ ÖH ; tai sen farmaseuttisesti hyväksyttävä suola.
10. Patenttivaatimuksen 1 mukainen yhdiste, jolloin kyseinen yhdiste on A OH HNT OY OM NH NEN OH od ofl ITÄ, Q a - HS OH tai sen farmaseuttisesti hyväksyttävä suola.
11. Patenttivaatimuksen 1 mukainen yhdiste, jolloin kyseinen yhdiste on
EP4051688 Nan NA m S MYY JA OLA Ho i n. Noi HÖ OR ; tai sen farmaseuttisesti hyväksyttävä suola.
12. Patenttivaatimuksen 1 mukainen yhdiste, jolloin kyseinen yhdiste on SN HN, | > NN m < oo” N AA SK UPN "he CT 5 HO OH : tai sen farmaseuttisesti hyväksyttävä suola.
13. Patenttivaatimuksen 1 mukainen yhdiste, jolloin kyseinen yhdiste on i HN=N vB KA > v0 0, KA O II A no NY NG HÖ OH i tai sen farmaseuttisesti hyväksyttävä suola.
14. Lääkekoostumus, joka käsittää jonkin patenttivaatimuksen 1-13 mukaista yhdistettä tai sen farmaseuttisesti hyväksyttävää suolaa ja farmaseuttisesti hyväksyttävää apuainetta.
15. Jonkin patenttivaatimuksen 1-13 mukainen yhdiste tai suola tai patenttivaatimuksen 14 mukainen lääkekoostumus käytettäväksi menetelmässä hoidettavan syövän hoitamiseksi, jolloin menetelmä käsittää kyseisen yhdisteen, suolan tai koostumuksen antamisen hoidettavalle.
16. Patenttivaatimuksen 15 mukaisesti käytettävä yhdiste, suola tai koostumus, jolloin
EP4051688 6 syöpä on keuhkosyöpä, melanooma, rintasyöpä, munasarjasyöpä, kolorektaalinen syöpä, mahasyöpä, sappirakon syöpä, eturauhassyöpä, munuaissyöpä tai lymfooma ja/tai jolloin syöpä ilmentää CD73:a tai CD73:n ilmentyminen lisääntyy syövässä.
17. Patenttivaatimuksen 15 mukaisesti käytettävä yhdiste, suola tai koostumus, jolloin syöpä on leukemia tai multippeli myelooma.
18. Patenttivaatimuksen 15 mukaisesti käytettävä yhdiste, suola tai koostumus, jolloin syöpä on multippeli myelooma.
19. Patenttivaatimuksen 15 mukaisesti käytettävä yhdiste, suola tai koostumus, jolloin syöpä on ainoastaan seurantaa vaativa multippeli myelooma, ei-sekretorinen myelooma, osteoskleroottinen myelooma, plasmasoluleukemia, — yksittäinen plasmasytooma tai ekstramedullaarinen plasmasytooma.
20. Jonkin patenttivaatimuksen 15—19 mukaisesti käytettävä yhdiste, suola tai koostumus, jolloin menetelmä käsittää lisäksi toisen terapeuttisen aineen antamisen; jolloin valinnaisesti toinen terapeuttinen aine on kemoterapeuttinen aine tai immunoterapia-aine.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928138P | 2019-10-30 | 2019-10-30 | |
| US202062987806P | 2020-03-10 | 2020-03-10 | |
| US202063088646P | 2020-10-07 | 2020-10-07 | |
| PCT/US2020/057996 WO2021087136A1 (en) | 2019-10-30 | 2020-10-29 | Cd73 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4051688T3 true FI4051688T3 (fi) | 2025-06-27 |
Family
ID=75686256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20883288.1T FI4051688T3 (fi) | 2019-10-30 | 2020-10-29 | Cd73:n estäjiä |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US11530236B2 (fi) |
| EP (2) | EP4596048A3 (fi) |
| JP (2) | JP7544815B2 (fi) |
| KR (2) | KR102653726B1 (fi) |
| CN (2) | CN116854758A (fi) |
| AU (1) | AU2020375914B2 (fi) |
| CA (1) | CA3159248C (fi) |
| DK (1) | DK4051688T3 (fi) |
| ES (1) | ES3034168T3 (fi) |
| FI (1) | FI4051688T3 (fi) |
| IL (2) | IL308293B1 (fi) |
| MX (1) | MX2022005256A (fi) |
| PL (1) | PL4051688T3 (fi) |
| PT (1) | PT4051688T (fi) |
| SI (1) | SI4051688T1 (fi) |
| TW (1) | TWI830962B (fi) |
| WO (1) | WO2021087136A1 (fi) |
| ZA (1) | ZA202204941B (fi) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| SG11202010790XA (en) | 2018-04-30 | 2020-11-27 | Oric Pharmaceuticals Inc | Cd73 inhibitors |
| EP4596048A3 (en) * | 2019-10-30 | 2025-11-19 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| WO2024059609A1 (en) * | 2022-09-14 | 2024-03-21 | Oric Pharmaceuticals, Inc. | Pharmaceutical forms of a cd73 inhibitor |
| WO2025111247A1 (en) * | 2023-11-20 | 2025-05-30 | Oric Pharmaceuticals, Inc. | Treatment of refractory multiple myeloma |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1023991A (en) | 1911-07-29 | 1912-04-23 | Firm B Byers | Anti-rail-creeper and splice-bar. |
| EP0477454A1 (en) | 1990-09-28 | 1992-04-01 | Merrell Dow Pharmaceuticals Inc. | Novel phosphonate derivatives of certain nucleosides |
| AU2002232660A1 (en) | 2000-12-15 | 2002-06-24 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| US20090029949A1 (en) | 2006-05-25 | 2009-01-29 | Parrill-Baker Abby L | GPCR Ligands Identified by Computational Modeling |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| US20090274686A1 (en) | 2008-05-02 | 2009-11-05 | Yat Sun Or | Nucleoside phosphonate derivatives |
| MA39986A (fr) | 2014-04-25 | 2017-03-01 | Vitae Pharmaceuticals Inc | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer |
| CN104530166B (zh) | 2014-12-04 | 2016-08-24 | 陕西汉江药业集团股份有限公司 | 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法 |
| CN112358551B (zh) * | 2014-12-12 | 2024-02-02 | 2赛文缇生物公司 | Bcma嵌合抗原受体 |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| LT3399984T (lt) | 2016-01-08 | 2023-11-10 | Arcus Biosciences, Inc. | 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas |
| TWI767937B (zh) | 2016-09-09 | 2022-06-21 | 美商卡利泰拉生物科技公司 | 外核苷酸酶抑制劑及其使用方法 |
| WO2018067424A1 (en) * | 2016-10-03 | 2018-04-12 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| EP3541396A4 (en) * | 2016-11-18 | 2020-07-22 | Arcus Biosciences, Inc. | CD73-MEDIATED IMMUNOSUPPRESSION INHIBITORS |
| WO2018119284A1 (en) | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| EP3600273A4 (en) * | 2017-03-31 | 2021-01-20 | Peloton Therapeutics, Inc. | CD73 INHIBITORS AND USES THEREOF |
| WO2018208727A1 (en) | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| WO2018208980A1 (en) * | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN111094317B (zh) | 2017-12-29 | 2023-03-31 | 上海和誉生物医药科技有限公司 | 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用 |
| SG11202010790XA (en) | 2018-04-30 | 2020-11-27 | Oric Pharmaceuticals Inc | Cd73 inhibitors |
| TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| EP3810617A4 (en) | 2018-06-21 | 2022-06-29 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| EP3843714B1 (en) | 2018-08-27 | 2025-11-12 | Arcus Biosciences, Inc. | Cd73 inhibitors |
| KR20220024629A (ko) | 2019-06-20 | 2022-03-03 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 엑토뉴클레오티다제 억제제 및 이의 사용 방법 |
| EP3999517A4 (en) | 2019-07-16 | 2023-07-12 | Oric Pharmaceuticals, Inc. | CD73 INHIBITORS |
| EP4596048A3 (en) * | 2019-10-30 | 2025-11-19 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
-
2020
- 2020-10-29 EP EP25170469.8A patent/EP4596048A3/en active Pending
- 2020-10-29 PT PT208832881T patent/PT4051688T/pt unknown
- 2020-10-29 JP JP2022525101A patent/JP7544815B2/ja active Active
- 2020-10-29 CN CN202310805820.7A patent/CN116854758A/zh active Pending
- 2020-10-29 WO PCT/US2020/057996 patent/WO2021087136A1/en not_active Ceased
- 2020-10-29 CA CA3159248A patent/CA3159248C/en active Active
- 2020-10-29 IL IL308293A patent/IL308293B1/en unknown
- 2020-10-29 DK DK20883288.1T patent/DK4051688T3/da active
- 2020-10-29 US US17/083,871 patent/US11530236B2/en active Active
- 2020-10-29 FI FIEP20883288.1T patent/FI4051688T3/fi active
- 2020-10-29 CN CN202080091505.7A patent/CN114929721B/zh active Active
- 2020-10-29 KR KR1020227018155A patent/KR102653726B1/ko active Active
- 2020-10-29 TW TW109137697A patent/TWI830962B/zh active
- 2020-10-29 ES ES20883288T patent/ES3034168T3/es active Active
- 2020-10-29 EP EP20883288.1A patent/EP4051688B1/en active Active
- 2020-10-29 IL IL292570A patent/IL292570B2/en unknown
- 2020-10-29 PL PL20883288.1T patent/PL4051688T3/pl unknown
- 2020-10-29 US US17/771,711 patent/US20220411459A1/en active Pending
- 2020-10-29 SI SI202030633T patent/SI4051688T1/sl unknown
- 2020-10-29 MX MX2022005256A patent/MX2022005256A/es unknown
- 2020-10-29 AU AU2020375914A patent/AU2020375914B2/en active Active
- 2020-10-29 KR KR1020247010203A patent/KR102727229B1/ko active Active
- 2020-12-08 US US17/114,993 patent/US11028120B2/en active Active
-
2021
- 2021-03-17 US US17/204,272 patent/US11130778B2/en active Active
-
2022
- 2022-05-05 ZA ZA2022/04941A patent/ZA202204941B/en unknown
- 2022-10-31 US US18/051,125 patent/US12018043B2/en active Active
-
2024
- 2024-05-10 US US18/660,815 patent/US12454544B2/en active Active
- 2024-08-15 JP JP2024135814A patent/JP7688769B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4051688T3 (fi) | Cd73:n estäjiä | |
| MY199730A (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| IL295569A (en) | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha | |
| FI3727461T3 (fi) | EPHA2:lle spesifisiä bisyklisiä peptidiligandeja | |
| IL257219A (en) | Prodrugs of glutamine analogs | |
| JP2019535720A5 (fi) | ||
| CR20210083A (es) | Compuestos de anillo fusionado | |
| FI4249456T3 (fi) | Psma:ta sitova kaksoismuotoinen radioaktiivinen merkkiaine ja terapeuttinen aine | |
| AU2016256469A8 (en) | Methods for treating cancer | |
| UY38296A (es) | Derivados de 3–(5–amino–1–oxoisoindolin–2–il)piperidin–2,6–diona y sus usos | |
| JP2019529500A5 (fi) | ||
| GEP20247627B (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| MX2019006296A (es) | Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas. | |
| MX2020007974A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| WO2018044937A3 (en) | Compositions and methods for treating a tumor suppressor deficient cancer | |
| EP4446301A3 (en) | Heterocyclic compounds for cancer imaging and treatment and methods for their use | |
| AU2020234961C1 (en) | Charged ion channel blockers and methods for use | |
| AR108265A1 (es) | Derivados de feniltriazol sustituidos con amida y usos de estos | |
| RU2017138468A (ru) | Антитела против человеческого her3, имеющие низкое содержание фукозы, и области их применения | |
| FI3837256T3 (fi) | Ureayhdisteitä ja koostumuksia smarca2/brm-atpaasiestäjinä | |
| EA201891241A1 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
| PH12020550984B1 (en) | Metallic material surface treatment agent, metallic material having surface treatment coating, and manufacturing method therefor | |
| MX2024001424A (es) | Compuesto radiomarcado y uso del mismo. | |
| JP2017530947A5 (fi) |